Xinmin Zhao

Learn More
  • Xinmin Zhao, Norman I Badler, Mark Steedman, Ahmed Shabana, Richard Paul, Lynn Bonnie +21 others
  • 1996
Acknowledgment First and foremost, I would like to express my deepest gratitude to my advisor, Dr. Norman I. Badler, for his invaluable guidance and advice, for his confidence in me from the beginning to the end, for all the freedom to pursue the research topics that interest me the most, and for the excellent research environment that he fosters at the(More)
Lactate dehydrogenase 5 (LDH-5) is one of the major isoenzymes catalyzing the biochemical process of pyruvate to lactate. The purpose of this study was to investigate the expression of serum LDH-5 and test whether this enzyme is regulated by tumor hypoxia and represents a prognostic marker in patients with Non-Hodgkin's lymphoma (NHL). In this study, LDH-5(More)
BACKGROUND YN968D1 (Apatinib) selectively inhibits phosphorylation of VEGFR-2 and tumor angiogenesis in mice model. The study was conducted to determine the maximum tolerated dose (MTD), safety profile, pharmacokinetic variables, and antitumor activity in advanced solid malignancies. METHODS This dose-escalation study was conducted according to the(More)
BACKGROUND To assess prognostic and predictive effects of clinical and biochemical factors in our published randomized study of a weekly low dose (metronomic arm) versus a conventional dosage of zoledronic acid (conventional arm) in breast cancer patients with bone metastases. METHODS Treatment outcome of 60 patients with bone metastases were used to(More)
Lung cancer is the leading cause of cancer-related death in the world. Previous report has identified ribosomal protein s15a (RPS15A) as a TGF-β-responsible gene in the lung adenocarcinoma cell line A549. In this study, we used specific si-RNA to downregulate RPS15A expression in A549 cells and found that decreased RPS15A expression significantly inhibited(More)
Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with bone metastasis, by reducing the risk of fracture, spinal cord compression, and hypercalcemia. Zoledronic acid, the most frequently used intravenous agent, has been traditionally administered on a monthly dosing schedule. Preclinical studies have(More)